Development and in vitro evaluation of liposomes and immunoliposomes containing 5-fluorouracil and R-phycoerythrin as a potential phototheranostic system for colorectal cancer
Beilstein Journal of Nanotechnology · 09.01.2026 · 17 · 97-121
DOI: 10.3762/bjnano.17.7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Beilstein Journal of Nanotechnology, online erschienen am 09.01.2026. Verfasst von Raissa Rodrigues Camelo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Ceará, Faculty of Pharmacy, Dentistry and Nursing, Department of Pharmacy, Fortaleza, Ceará, Brazil. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de São Paulo, Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
5-Fluorouracil (5-FU) is the first-line drug for the treatment of colorectal cancer (CRC), which is considered the third most prevalent type of cancer in the world. R-phycoerythrin (R-PE) is a phycobiliprotein isolated from red algae such as Solieria filiformis , with fluorescent properties, photodynamic activity and potential for cancer treatment. However, 5-FU toxicity promotes several side effects and R-PE low stability hampers its clinical use. Thus, the present work aimed to develop co-encapsulated liposomes system for co-delivery of 5-FU and R-PE as theranostic nanosystems for CRC, as well as immunoliposomes targeted with the anti-EGFR monoclonal antibody, cetuximab, as a strategy for targeted delivery to EGFR-positive CRC. To the best of our knowledge, this is the first study to report the development and in vitro evaluation of liposomes and immunoliposomes co-encapsulating 5-FU and R-PE. Thus, liposomes containing 25 mg or 50 mg of soybean phosphatidylcholine (SPC), diesterolphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DPPC), hydrogenated soybean phosphatidylcholine (HSPC) with cholesterol (Chol) and 1,2-distearol- sn -glycero-3-phosphoethanolamine- N -[amino(polyethylene glycol)-2000] (DSPE-PEG 2000) were prepared and characterized. Among the liposomes, those containing HSPC lipid at 50 mg showed a low polydispersity index (PDI) (0.100 ± 0.022), small size (103.43 ± 1.31 nm), and slightly negative zeta potential (−12.23 ± 0.35 mV). The encapsulation efficiency (EE%) was 94 ± 2.4% for R-PE and 42 ± 2.8% for 5-FU. Regarding the stability study, the liposomes maintained vesicle size, PDI and zeta potential values in a stable range. From the choice of the 50 mg HSPC liposome, the immunoliposomes were developed. The selected immunoliposomes, composed HSPC/DOPE/Chol/DSPE-PEG-Mal in a ratio of 64:10:22.2:3.7, were named HSPC IM 07. This formulation presented low PDI (0.185 ± 0.01), small vesicle size (99.45 ± 1.81 nm), negative zeta potential (−14.8 ± 0.81 mV) and antibody conjugation efficiency of 34.4%. Topographical AFM analysis showed that HSPC-IM-R-PE presented significantly higher surface roughness and viscoelastic contrast, indicating successful antibody anchoring. For cell viability in the HCT-116 CCR cell line, the IC 50 values for immunoliposomes were higher than those for liposomes. Also, for phototoxicity experiments it was found a reduction in IC 50 for all groups tested. The internalization of R-PE was verified, highlighting a greater internalization in the immunoliposome within 24 h. Thus, the HSPC 50 formulation containing R-PE and 5-FU, functionalized with cetuximab, is a promising alternative for the development of co-encapsulation delivery systems as a phototheranostic nanocarriers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Federal University of Ceará, Faculty of Pharmacy, Dentistry and Nursing, Department of Pharmacy, Fortaleza, Ceará, Brazil.
- Federal University of Ceará, College of Medicine, Department of Physiology and Pharmacology, Fortaleza, Ceará, Brazil.
- School of Pharmaceutical Sciences of Ribeirao Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
- Federal University of Ceará, Center of Technology, Department of Chemical Engineering, Fortaleza, Ceará, Brazil.
ORCID-Profile: Claudia Pessoa, Daniel Giuliano Cerri, Raquel Petrilli
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico
Zitieren
APA
Rodrigues Camelo, R., Vandesmet, V. C. S., Vital Baccallini, O., de Brito Vieira Neto, J., Moreira, T. D. S., Almeida Moreira Leal, L. K., Pessoa, C., Cerri, D. G., Bentley, M. V. L. B., Eloy, J. O., Júnior, I. J. D. S., & Petrilli, R. (2026). Development and in vitro evaluation of liposomes and immunoliposomes containing 5-fluorouracil and R-phycoerythrin as a potential phototheranostic system for colorectal cancer. Beilstein Journal of Nanotechnology, 17, 97-121. https://doi.org/10.3762/bjnano.17.7
Vancouver
Rodrigues Camelo R, Vandesmet VCS, Vital Baccallini O, de Brito Vieira Neto J, Moreira TDS, Almeida Moreira Leal LK, et al. Development and in vitro evaluation of liposomes and immunoliposomes containing 5-fluorouracil and R-phycoerythrin as a potential phototheranostic system for colorectal cancer. Beilstein Journal of Nanotechnology. 2026;17:97-121. doi:10.3762/bjnano.17.7
BibTeX
@article{RodriguesCamelo2026,
author = {Rodrigues Camelo, Raissa and Vandesmet, Vivianne Cortez Sombra and Vital Baccallini, Octavio and de Brito Vieira Neto, José and Moreira, Thais da Silva and Almeida Moreira Leal, Luzia Kalyne and Pessoa, Claudia and Cerri, Daniel Giuliano and Bentley, Maria Vitória Lopes Badra and Eloy, Josimar O and Júnior, Ivanildo José da Silva and Petrilli, Raquel},
title = {Development and in vitro evaluation of liposomes and immunoliposomes containing 5-fluorouracil and R-phycoerythrin as a potential phototheranostic system for colorectal cancer},
journal = {Beilstein Journal of Nanotechnology},
year = {2026},
volume = {17},
pages = {97--121},
doi = {10.3762/bjnano.17.7}
}
EUVIMED